ArticleOncotarget2017

Dramatic response of CTNNB1 and VEGFR-2 mutant temporal bone squamous cell carcinoma to bevacizumab in combination with pemetrexed.

Lai Wei et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.